Jordan

The Jordan Food and Drug Administration (JFDA) is the primary national authority responsible for regulating pharmaceuticals, medical devices, diagnostics, and increasingly digital health products in Jordan. Established under the Food and Drug Law No. 31 of 2008, the JFDA operates under the Ministry of Health and oversees product registration, post-market surveillance, import control, and quality assurance. All health products intended for the Jordanian market must obtain JFDA marketing authorization prior to commercialization, with distinct registration pathways applicable to pharmaceuticals, medical devices, and in-vitro diagnostics respectively. The approval process generally involves submission of a technical dossier, scientific evaluation, and in some cases facility inspection or local testing requirements.

Submission dossiers for pharmaceuticals are expected to follow the Common Technical Document (CTD) format, and the JFDA increasingly references international standards including those from the International Council for Harmonisation (ICH) and the Global Harmonization Task Force (GHTF) for medical devices. A locally registered legal representative or agent is mandatory for foreign manufacturers seeking product registration. Jordan has implemented a reliance mechanism that allows expedited review for products already approved by stringent regulatory authorities such as the US FDA, EMA, or Health Canada, which can significantly shorten timelines. Recent reforms have focused on strengthening post-market surveillance, introducing electronic submission platforms, and aligning device classification with international frameworks to improve regulatory efficiency and transparency.

Public procurement of health products in Jordan is primarily centralized through the Ministry of Health (MOH), which manages national tenders for pharmaceuticals, medical devices, and diagnostic supplies destined for public hospitals and primary healthcare centers. The MOH's Procurement and Supply Directorate coordinates annual and periodic tenders, with award decisions based on technical compliance, pricing, and registration status with the JFDA. The Royal Medical Services (RMS), which serves military and security personnel and their dependents, operates its own independent procurement system and represents a significant additional public sector channel. Price control mechanisms enforced by the JFDA apply to pharmaceuticals, and products must hold valid registration to be eligible for public tender participation.

The private sector in Jordan is well developed and accounts for a substantial share of health product consumption, with distribution channeled through licensed private importers, wholesalers, and retail pharmacies operating under JFDA oversight. Jordan also serves as a regional hub for international and donor-funded health programs, with organizations such as UNICEF, the United Nations Relief and Works Agency (UNRWA), the Global Fund, and USAID-funded initiatives procuring health commodities for refugee populations and vulnerable communities, particularly given Jordan's significant Syrian refugee caseload. UNRWA in particular maintains procurement operations based in Jordan covering its regional mandate. Local manufacturing is present in the pharmaceutical sector, with a number of Jordanian manufacturers holding WHO Good Manufacturing Practice (GMP) certification and exporting regionally; public tender policies offer competitive advantages to locally manufactured products, reflecting government interest in supporting the domestic pharmaceutical industry.